Key Points
- Illumina insider Scott Davies sold 615 shares for $123,000 at an average price of $200 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 2.94% to 20,338 shares.
- Illumina reported quarterly EPS of $1.31 and revenue of $1.16 billion, beating analyst estimates, while revenue increased 9.4% year over year. The company set fiscal 2026 EPS guidance at $5.30–$5.40.
- Shares opened at $198.16 after recently reaching a 52-week high, but valuation concerns remain: analysts’ average rating is “Hold,” with an average price target of $188.40 despite several recent target increases.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) insider Scott Davies sold 615 shares of the business's stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the sale, the insider directly owned 20,338 shares in the company, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Illumina Trading Down 3.4%
Illumina stock opened at $198.16 on Tuesday. The company has a market cap of $29.98 billion, a price-to-earnings ratio of 36.97, a P/E/G ratio of 2.94 and a beta of 1.44. The firm has a 50-day moving average of $177.78 and a 200-day moving average of $147.61. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.37 earnings per share for the current fiscal year.
Illumina News Roundup
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Raised revenue outlook and clinical-sequencing demand support the stock. Illumina reported second-quarter revenue of $1.159 billion, up from $1.059 billion a year earlier, and raised its 2026 revenue forecast to $4.60 billion-$4.64 billion. Management’s focus on clinical sequencing and multi-omics is reinforcing expectations for continued growth. Why Illumina Is Up After Raising 2026 Revenue Outlook
- Positive Sentiment: Analysts raised their valuation expectations. Piper Sandler reaffirmed its “overweight” rating and increased its price target to $225 from $200. Other recent reports cited price targets of $210 and $230, indicating that some analysts see additional upside despite the stock’s recent rally. Piper Sandler Rating Report Illumina Price Target Raised to $210 Illumina Price Target Raised to $230
- Neutral Sentiment: Momentum is strong, but investors are questioning how much upside remains. ILMN reached a fresh 52-week high after more than doubling over the past year. The move reflects improving fundamentals, but the elevated share price increases sensitivity to any execution or guidance disappointment. Illumina Hits Fresh High
- Negative Sentiment: Valuation and cash-flow concerns could weigh on returns. One analysis estimates the shares may be approximately 19% overvalued, while another notes that market multiples appear expensive even though a discounted-cash-flow model suggests potential upside. Broader concerns include whether strong cash generation will translate into efficient spending and sustained growth. Illumina Could Be Overvalued Cash-Producing Stocks That Concern Us
- Negative Sentiment: An insider sold shares. Scott M. Davies sold 615 shares worth $123,000 under a pre-arranged Rule 10b5-1 plan. The sale was relatively small and leaves him with 20,338 shares, but it is still a modest negative signal for sentiment.
Institutional Trading of Illumina
Institutional investors and hedge funds have recently bought and sold shares of the business. Elyxium Wealth LLC acquired a new position in shares of Illumina during the 4th quarter worth approximately $25,000. Creative Capital Management Investments LLC raised its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock valued at $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in Illumina during the 4th quarter valued at $26,000. Laurel Wealth Advisors LLC acquired a new stake in Illumina during the 4th quarter valued at $26,000. Finally, Activest Wealth Management boosted its position in Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after purchasing an additional 215 shares during the period. Institutional investors own 89.42% of the company's stock.
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of analyst reports. Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. raised their target price on shares of Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday. Barclays boosted their target price on shares of Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a report on Friday. Sanford C. Bernstein reaffirmed a "market perform" rating and set a $215.00 price target on shares of Illumina in a research report on Friday. Finally, Canaccord Genuity Group increased their price target on shares of Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $188.40.
Read Our Latest Report on Illumina
About Illumina
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
